Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis

Cell Metabolism

Volumn 24, Issue 6, 2016, Pages 848-862

  Wang, Xiaobo ^a   Zheng, Ze ^a   Caviglia, Jorge Matias ^a   Corey, Kathleen E ^b,c   Herfel, Tina M ^d   Cai, Bishuang ^a   Masia, Ricard ^b,c   Chung, Raymond T ^b,c   Lefkowitch, Jay H ^e   Schwabe, Robert F ^a   Tabas, Ira ^a,e  

^a Columbia University ^*  (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Envigo   (United States)

^e Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; SONIC HEDGEHOG PROTEIN; TAZ PROTEIN; UNCLASSIFIED DRUG; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; WWTR1 PROTEIN, HUMAN; WWTR1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; GENE ACTIVATION; GENE SILENCING; HEPATITIS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; STELLATE CELL; ANIMAL; C57BL MOUSE; COMPLICATION; DIET; DISEASE COURSE; DISEASE MODEL; GENETICS; HEPATIC STELLATE CELL; INFLAMMATION; LIVER; LIVER CIRRHOSIS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BASE SEQUENCE; CELL DEATH; DIET; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE SILENCING; HEDGEHOG PROTEINS; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER CIRRHOSIS; MALE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85003945921     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.09.016     Document Type: Article

References (55)

1. Abdelmalek, M.F., Suzuki, A., Guy, C., Unalp-Arida, A., Colvin, R., Johnson, R.J., Diehl, A.M., Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51 (2010), 1961–1971.
2. Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., Mills, P.R., Keach, J.C., Lafferty, H.D., Stahler, A., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397.e10.
3. Angulo, P., Machado, M.V., Diehl, A.M., Fibrosis in nonalcoholic fatty liver disease: mechanisms and clinical implications. Semin. Liver Dis. 35 (2015), 132–145.
4. Bertero, T., Cottrill, K.A., Annis, S., Bhat, B., Gochuico, B.R., Osorio, J.C., Rosas, I., Haley, K.J., Corey, K.E., Chung, R.T., et al. A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. Sci. Rep., 5, 2015, 18277.
5. Bieghs, V., Hendrikx, T., van Gorp, P.J., Verheyen, F., Guichot, Y.D., Walenbergh, S.M., Jeurissen, M.L., Gijbels, M., Rensen, S.S., Bast, A., et al. The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice. Gastroenterology 144 (2013), 167–178.e1.
6. Bohinc, B.N., Diehl, A.M., Mechanisms of disease progression in NASH: new paradigms. Clin. Liver Dis. 16 (2012), 549–565.
7. Butler, A.A., Cone, R.D., The melanocortin receptors: lessons from knockout models. Neuropeptides 36 (2002), 77–84.
8. Chan, F.K., Luz, N.F., Moriwaki, K., Programmed necrosis in the cross talk of cell death and inflammation. Annu. Rev. Immunol. 33 (2015), 79–106.
9. Charlton, M., Krishnan, A., Viker, K., Sanderson, S., Cazanave, S., McConico, A., Masuoko, H., Gores, G., Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am. J. Physiol. Gastrointest. Liver Physiol. 301 (2011), G825–G834.
10. Corey, K.E., Kaplan, L.M., Obesity and liver disease: the epidemic of the twenty-first century. Clin. Liver Dis. 18 (2014), 1–18.
11. Day, C.P., James, O.F., Steatohepatitis: a tale of two “hits”?. Gastroenterology 114 (1998), 842–845.
12. Dixon, L.J., Berk, M., Thapaliya, S., Papouchado, B.G., Feldstein, A.E., Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab. Invest. 92 (2012), 713–723.
13. Dumenco, L., Oguey, D., Wu, J., Messier, N., Fausto, N., Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. Hepatology 22 (1995), 1279–1288.
14. Friedman, S.L., Mechanisms of hepatic fibrogenesis. Gastroenterology 134 (2008), 1655–1669.
15. Gautheron, J., Vucur, M., Reisinger, F., Cardenas, D.V., Roderburg, C., Koppe, C., Kreggenwinkel, K., Schneider, A.T., Bartneck, M., Neumann, U.P., et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol. Med. 6 (2014), 1062–1074.
16. Hebbard, L., George, J., Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8 (2011), 35–44.
17. Hwang, S.M., Jin, M., Shin, Y.H., Ki Choi, S., Namkoong, E., Kim, M., Park, M.Y., Park, K., Role of LPA and the Hippo pathway on apoptosis in salivary gland epithelial cells. Exp. Mol. Med., 46, 2014, e125.
18. Ioannou, G.N., The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol. Metab. 27 (2016), 84–95.
19. Ishimoto, T., Lanaspa, M.A., Rivard, C.J., Roncal-Jimenez, C.A., Orlicky, D.J., Cicerchi, C., McMahan, R.H., Abdelmalek, M.F., Rosen, H.R., Jackman, M.R., et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 58 (2013), 1632–1643.
20. Jolley, C.D., Dietschy, J.M., Turley, S.D., Genetic differences in cholesterol absorption in 129/Sv and C57BL/6 mice: effect on cholesterol responsiveness. Am. J. Physiol. 276 (1999), G1117–G1124.
21. Joshi-Barve, S., Barve, S.S., Amancherla, K., Gobejishvili, L., Hill, D., Cave, M., Hote, P., McClain, C.J., Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 46 (2007), 823–830.
22. Kohli, R., Kirby, M., Xanthakos, S.A., Softic, S., Feldstein, A.E., Saxena, V., Tang, P.H., Miles, L., Miles, M.V., Balistreri, W.F., et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52 (2010), 934–944.
23. Lisowski, L., Dane, A.P., Chu, K., Zhang, Y., Cunningham, S.C., Wilson, E.M., Nygaard, S., Grompe, M., Alexander, I.E., Kay, M.A., Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506 (2014), 382–386.
24. Liu, C.Y., Lv, X., Li, T., Xu, Y., Zhou, X., Zhao, S., Xiong, Y., Lei, Q.Y., Guan, K.L., PP1 cooperates with ASPP2 to dephosphorylate and activate TAZ. J. Biol. Chem. 286 (2011), 5558–5566.
25. Liu, F., Lagares, D., Choi, K.M., Stopfer, L., Marinković, A., Vrbanac, V., Probst, C.K., Hiemer, S.E., Sisson, T.H., Horowitz, J.C., et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 308 (2015), L344–L357.
26. Luedde, T., Kaplowitz, N., Schwabe, R.F., Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 147 (2014), 765–783.e4.
27. Machado, M.V., Michelotti, G.A., Pereira, T.A., Xie, G., Premont, R., Cortez-Pinto, H., Diehl, A.M., Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. J. Hepatol. 63 (2015), 962–970.
28. Mederacke, I., Hsu, C.C., Troeger, J.S., Huebener, P., Mu, X., Dapito, D.H., Pradere, J.P., Schwabe, R.F., Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun., 4, 2013, 2823.
29. Mitani, A., Nagase, T., Fukuchi, K., Aburatani, H., Makita, R., Kurihara, H., Transcriptional coactivator with PDZ-binding motif is essential for normal alveolarization in mice. Am. J. Respir. Crit. Care Med. 180 (2009), 326–338.
30. Miura, K., Yang, L., van Rooijen, N., Brenner, D.A., Ohnishi, H., Seki, E., Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 57 (2013), 577–589.
31. Mu, X., Español-Suñer, R., Mederacke, I., Affò, S., Manco, R., Sempoux, C., Lemaigre, F.P., Adili, A., Yuan, D., Weber, A., et al. Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. J. Clin. Invest. 125 (2015), 3891–3903.
32. Nishio, M., Sugimachi, K., Goto, H., Wang, J., Morikawa, T., Miyachi, Y., Takano, Y., Hikasa, H., Itoh, T., Suzuki, S.O., et al. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. Proc. Natl. Acad. Sci. USA 113 (2016), E71–E80.
33. Piersma, B., Bank, R.A., Boersema, M., Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge. Front Med (Lausanne), 2, 2015, 59.
34. Puche, J.E., Saiman, Y., Friedman, S.L., Hepatic stellate cells and liver fibrosis. Compr. Physiol. 3 (2013), 1473–1492.
35. Rawson, R.B., An ARC light on lipid metabolism. Cell Metab. 4 (2006), 181–183.
36. Razzaque, M.S., Soegiarto, D.W., Chang, D., Long, F., Lanske, B., Conditional deletion of Indian hedgehog from collagen type 2alpha1-expressing cells results in abnormal endochondral bone formation. J. Pathol. 207 (2005), 453–461.
37. Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
38. Saito, A., Nagase, T., Hippo and TGF-β interplay in the lung field. Am. J. Physiol. Lung Cell. Mol. Physiol. 309 (2015), L756–L767.
39. Shimamura, T., Fujisawa, T., Husain, S.R., Kioi, M., Nakajima, A., Puri, R.K., Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J. Immunol. 181 (2008), 4656–4665.
40. Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 13 (2015), 643–654.e1 9, quiz e39–e40.
41. Subramanian, S., Goodspeed, L., Wang, S., Kim, J., Zeng, L., Ioannou, G.N., Haigh, W.G., Yeh, M.M., Kowdley, K.V., O'Brien, K.D., et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J. Lipid Res. 52 (2011), 1626–1635.
42. Syn, W.K., Oo, Y.H., Pereira, T.A., Karaca, G.F., Jung, Y., Omenetti, A., Witek, R.P., Choi, S.S., Guy, C.D., Fearing, C.M., et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 51 (2010), 1998–2007.
43. Syn, W.K., Choi, S.S., Liaskou, E., Karaca, G.F., Agboola, K.M., Oo, Y.H., Mi, Z., Pereira, T.A., Zdanowicz, M., Malladi, P., et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 53 (2011), 106–115.
44. Teratani, T., Tomita, K., Suzuki, T., Oshikawa, T., Yokoyama, H., Shimamura, K., Tominaga, S., Hiroi, S., Irie, R., Okada, Y., et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 142 (2012), 152–164.e10.
45. Van Rooyen, D.M., Larter, C.Z., Haigh, W.G., Yeh, M.M., Ioannou, G., Kuver, R., Lee, S.P., Teoh, N.C., Farrell, G.C., Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141 (2011), 1393–1403, 1403.e1–1403.e5.
46. White, D.L., Kanwal, F., El-Serag, H.B., Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 10 (2012), 1342–1359.e2, e2.
47. Wouters, K., van Gorp, P.J., Bieghs, V., Gijbels, M.J., Duimel, H., Lütjohann, D., Kerksiek, A., van Kruchten, R., Maeda, N., Staels, B., et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48 (2008), 474–486.
48. Xin, M., Kim, Y., Sutherland, L.B., Murakami, M., Qi, X., McAnally, J., Porrello, E.R., Mahmoud, A.I., Tan, W., Shelton, J.M., et al. Hippo pathway effector Yap promotes cardiac regeneration. Proc. Natl. Acad. Sci. USA 110 (2013), 13839–13844.
49. Yamada, K., Mizukoshi, E., Sunagozaka, H., Arai, K., Yamashita, T., Takeshita, Y., Misu, H., Takamura, T., Kitamura, S., Zen, Y., et al. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis. Liver Int. 35 (2015), 582–590.
50. Younossi, Z.M., Page, S., Rafiq, N., Birerdinc, A., Stepanova, M., Hossain, N., Afendy, A., Younoszai, Z., Goodman, Z., Baranova, A., A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes. Surg. 21 (2011), 431–439.
51. Yu, F.X., Zhao, B., Guan, K.L., Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163 (2015), 811–828.
52. Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Quaranta, E., Bodega, B., Rosato, A., Bicciato, S., Cordenonsi, M., Piccolo, S., Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat. Cell Biol. 17 (2015), 1218–1227.
53. Zanconato, F., Cordenonsi, M., Piccolo, S., YAP/TAZ at the roots of cancer. Cancer Cell 29 (2016), 783–803.
54. Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J.D., Wang, C.Y., Chinnaiyan, A.M., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22 (2008), 1962–1971.
55. Zhao, B., Li, L., Lei, Q., Guan, K.L., The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 24 (2010), 862–874.